Hunan Er-Kang Stock Hits Day Low of CNY 3.25 Amid Price Pressure

Hunan Er-Kang Pharmaceutical Co., Ltd. experienced significant volatility today, with the stock hitting an intraday low of CNY 3.25, reflecting a decline of 5.44% on June 8, 2026. This performance starkly contrasts with the China Shanghai Composite, which fell by only 1.7% during the same period. Over the past week, Hunan Er-Kang has seen a notable drop of 12.47%, and its monthly performance is down by 23.96%. Year-to-date, the stock has decreased by 3.23%, while its performance over the last year shows a modest gain of 2.8%, significantly lagging behind the China Shanghai Composite's 16.95% increase. The company's financial metrics indicate challenges, including a low Return on Capital Employed (ROCE) of 0.47%, suggesting limited profitability relative to its capital. Additionally, net sales have declined at an annual rate of 12.85% over the last five years, and the latest financial results show a net profit of CNY -407.3 million, down 27.32%. With a market capitalization of CNY 4,668 million, Hunan Er-Kang continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.